Navigation Links
Cancer Patients May Reduce Fast Growing Breast Cancer Recurrences: Findings Reported at 2010 San Antonio Breast Cancer Symposium
Date:12/10/2010

THE WOODLANDS, Texas, Dec. 10, 2010 /PRNewswire/ -- Joyce O'Shaughnessy, M.D., medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research, and medical oncologist with Texas Oncology-Baylor Sammons Cancer Center, presented her study findings today at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.

(Logo: http://photos.prnewswire.com/prnh/20100517/DA06089LOGO)

Her captivating study titled "First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide Followed by Docetaxel with or without Capecitabine in High-Risk Early Breast Cancer" involved an innovative ten-year analysis focusing on high-risk early breast cancer. Her presentation provided an in-depth look at how faster growing breast cancers react to Xeloda® (capecitabine).

"Although the overall study results at the time of this analysis do not show that breast cancer recurrences are significantly decreased with the addition of Xeloda to standard chemotherapy, I think the study suggests that Xeloda may reduce recurrence of faster growing breast cancers," said Dr. O'Shaughnessy. "Hopefully longer follow-up will confirm these findings."

Dr. O'Shaughnessy is one of several internationally recognized investigators affiliated with US Oncology Research who participated in studies that are being presented, discussed and displayed Dec. 8-12 to a broad international audience of academic and private researchers and physicians from more than 90 countries. She a
'/>"/>

SOURCE US Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Hill-Rom Holdings, Inc. ... to a management presentation at the Morgan Stanley Global ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP ... available one hour after conclusion of the live event ...
(Date:8/27/2014)... DANVERS, Mass. , Aug. 27, 2014 North ... with a prestigious R&D 100 Award for the new OSRAM ... laser and LED-based white light module for microscopy, endoscopy and ... Xenon lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of ...
(Date:8/27/2014)... Aug. 27, 2014 Amgen (NASDAQ: ... Administration (FDA) has granted priority review designation for ivabradine ... is an oral drug that inhibits the I ... node, the body,s cardiac pacemaker. 1 Ivabradine works ... myocardial contractility or ventricular repolarization. 1 Heart failure ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... First U.S. Clinical Data on XIENCE V ... Follow-Up,Results from the ABSORB Bioabsorbable Stent Clinical ... /PRNewswire-FirstCall/ --,Abbott will present data from several ... during a number of late-breaking,clinical trial and ...
... La Jolla,Pharmaceutical Company today announced updated interim antibody,reduction ... (abetimus,sodium), its drug candidate for systemic lupus erythematosus,("lupus" ... that there is a definitive and significant dose ... mg doses of Riquent compared,with placebo (p=0.0001). These ...
Cached Medicine Technology:Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 2Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 4Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6
(Date:8/28/2014)... 28, 2014 The next episode of ... from Tallahassee, Fla. He’s a drama coach who longs ... frame has made achieving that dream impossible. , Featuring ... Weight Loss” airs Tuesday, September 2 (9:00-11:00 p.m., ET/PT) ... wears a big smile on the outside to hide ...
(Date:8/27/2014)... The report provides market analysis of “Military ... Finder, LIDAR, 3D scanner, Laser Weapon, Dazzlers, Laser sights, ... Altimeter) by Domain (Aerospace, Defense and Homeland Security) - ... MarketsandMarkets, and its application in the aerospace and defense ... Systems market is expected to register a CAGR of ...
(Date:8/27/2014)... FL (PRWEB) August 27, 2014 ... money-saving dental plans, has launched in the state ... access to quality, affordable dental care services at ... destination for Tennessee consumers looking to save money ... dental rates as a member of discount fee ...
(Date:8/27/2014)... National Resident Matching Program International ... Medical Education in Europe (AMEE) Conference being held at ... – September 3, 2014. As an exhibitor, NRMPI ... community, share the benefits of its matching services, and ... in countries throughout the world. , “Exhibiting ...
(Date:8/27/2014)... Arrow, OK (PRWEB) August 27, 2014 When ... their guests a comfortable bed to sleep without breaking the ... the market for a new foam mattress set for the ... to sleep on, Bedding Mart has it all during their ... stock up on some of the best mattresses for the ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Rod’s Journey Begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 4Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 2Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 3Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2Health News:Bedding Mart, Top Mattress Store in Broken Arrow Oklahoma, Announces a Huge Labor Day Sale 2
... accident, skull separating from her spine, has survived to tell ... ,A car crash slammed her into the dashboard. Her ... and other internal organs remained intact. The rare condition is ... no control over her head. ,Surgeons said her ...
... Since it is a very painful process, continuous attempts are ... the patient. ,Now researchers say that LHRH agonists ... the production of a female hormone that encourages some tumours ... often mimicking the action of a naturally occurring substance. ...
... affects to work, sleep and performance of other activities but ... and your concentration. ,This is the finding ... Rashiq at the University of Alberta. ,As a ... Pain Centre in Edmonton, Canada, the researchers studied 24 patients, ...
... a type of kidney malignancy called renal cancer according to ... Women's Hospital in Boston found that women and men who ... about 30 percent less likely to develop renal cell cancer ... drank beer, wine or liquor. ,Jung Eun Lee ...
... addition of folic acid to flour or bread mandatory in order ... ,After lengthy public consultations the Food Standards Agency (FSA) ... next month after it decides whether folic acid should be added ... the FSA's proposals, it will be the first time since the ...
... of Psychiatric and Mental Health Nursing in a recent report, ... health support to the victims of the 2005 Bali ... first explosions in 2002. ,Staff at the Royal ... recipients of vital personal support from mental health nurses. ...
Cached Medicine News:Health News:30-year-old Woman Survives 'internal Decapitation' 2Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:UK too Will Insist on Folic Acid in Bread 2Health News:UK too Will Insist on Folic Acid in Bread 3Health News:Bali Bombings Helped Improve Trauma Care 2Health News:Bali Bombings Helped Improve Trauma Care 3
... Most practitioners consider the HOPE nebulizer the ... have been made to put everything together in ... The result is our #11320 Adult HOPE Kit ... corrugated tubing and pediatric aerosol mask all in ...
... medication nebulizers offer a spill-proof design and ... a 45° angle. All medical nebulizers are ... variety of configurations are available., ,All ... ,Portex® medication nebulizers feature consistently fine ...
... delivery of medication as well as humidification, ... closed dilution, high volume, continuous medication nebulizer ... to patients. Its 200 ml reservoir and ... 8 hours of nebulized medication delivery at ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: